Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioXcel Therapeutics, Inc.BTAI · Entity 8380 | Director | January 09, 2026 | January 12, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP, Global R&D, CSO | June 16, 2014 | June 18, 2014 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioXcel Therapeutics, Inc.
Report date January 09, 2026 · Filed January 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.01 · Expires 2036-01-09 | Direct | 17,000 |
Reported balance
After 2026-01-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-09 · Grant · Acquired 17,000 · Balance 17,000 F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest and become exercisable on the earlier of the first anniversary of the date of grant or the day immediately prior to the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant, in either case, subject to the Reporting Person's continuing in service as a non-employee director through such vesting date.
VERTEX PHARMACEUTICALS INC / MA
Report date June 16, 2014 · Filed June 18, 2014
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 151,017 |
Reported balance
After 2014-06-16 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2014-06-16 · Exercise / conversion · Acquired 7,500 · Balance 151,017 |
| Common StockSEC Table I · non-derivative | Direct | 146,614 |
Reported balance
After 2014-06-16 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2014-06-16 · Sale · Disposed 4,403 · Balance 146,614 F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F2: Open market sales reported on this line occurred at a weighted average price of $67.72 (range $67.47 to $67.96). F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| Common StockSEC Table I · non-derivative | Direct | 145,114 |
Reported balance
After 2014-06-16 transaction · row 3
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 3 · 2014-06-16 · Sale · Disposed 1,500 · Balance 145,114 F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4: Open market sales reported on this line occurred at a weighted average price of $68.25 (range $68.04 to $68.86). |
| Common StockSEC Table I · non-derivative | Direct | 143,517 |
Reported balance
After 2014-06-16 transaction · row 5
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 5 · 2014-06-16 · Sale · Disposed 1,000 · Balance 143,517 F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6: Open market sales reported on this line occurred at a weighted average price of $70.29 (range $70.00 to $70.99). |
| Common StockSEC Table I · non-derivative | Direct | 144,517 |
Reported balance
After 2014-06-16 transaction · row 4
1 source rowRow 4 · 2014-06-16 · Sale · Disposed 597 · Balance 144,517 F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1. F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5: Open market sales reported on this line occurred at a weighted average price of $69.54 (range $69.15 to $69.95). |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.16 · Expires 2018-07-23 | Direct | 15,500 |
Reported balance
After 2014-06-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2014-06-16 · Exercise / conversion · Disposed 7,500 · Balance 15,500 F8: Fully vested. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 4,770 |
Reported balance
Holding disclosure · report date 2014-06-16 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 4,770 |
| Common StockSEC Table I · non-derivative | IndirectRevocable Trust | 5,568 |
Reported balance
Holding disclosure · report date 2014-06-16 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 5,568 |
| Common StockSEC Table I · non-derivative | IndirectCommon stock held in trust | 15,233 |
Reported balance
Holding disclosure · report date 2014-06-16 · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · Balance 15,233 F7: Common stock held in grantor retained annuity trust. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1.
F2: Open market sales reported on this line occurred at a weighted average price of $67.72 (range $67.47 to $67.96).
F3: Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4: Open market sales reported on this line occurred at a weighted average price of $68.25 (range $68.04 to $68.86).
F5: Open market sales reported on this line occurred at a weighted average price of $69.54 (range $69.15 to $69.95).
F6: Open market sales reported on this line occurred at a weighted average price of $70.29 (range $70.00 to $70.99).
F7: Common stock held in grantor retained annuity trust.
F8: Fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 06, 2004 Filed May 10, 2004 20:02 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 65,000 | $0.01 | $650.00 |
DisclosureSEC source: 0000875320-04-000051 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · CSO & SVP Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,840 F1 · shares: Stock grant made under 1996 Stock and Option Plan, vesting 50% on May 6, 2009, subject to acceleration upon achievement of a performance-based milestone based on Company profitability, and 50% on May 6, 2007. Read SEC document |
| March 17, 2004 Filed Mar 19, 2004 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock · Derivative | 14,400 | $0.00 Strike: $9.69 | $0.00 |
DisclosureSEC source: 0000875320-04-000020 · edgar.xml · derivative · entry 2 MUELLER PETER · CIK 0001256126 · CSO & SVP Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,800 Underlying: Common Stock · 14,400 shares Expires 2014-03-16 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 12/11/2003. Read SEC document |
| March 17, 2004 Filed Mar 19, 2004 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,920 | $0.01 | $19.20 |
DisclosureSEC source: 0000875320-04-000020 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · CSO & SVP Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,840 F1 · shares: Stock grant made under 1996 Stock and Option Plan, vesting on 3/17/2008, subject to acceleration upon achievement of certain performance-based milestones. Read SEC document |
| December 11, 2003 Filed Dec 15, 2003 21:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock · Derivative | 14,400 | $0.00 Strike: $9.07 | $0.00 |
DisclosureSEC source: 0000875320-03-000062 · edgar.xml · derivative · entry 2 MUELLER PETER · CIK 0001256126 · CSO & SVP Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,400 Underlying: Common Stock · 14,400 shares Expires 2013-12-11 F2 · derivative.exercise_date: Right to buy under 1996 Stock and Option Plan, vesting in 16 equal quarterly installments from 12/11/2003. Read SEC document |
| December 11, 2003 Filed Dec 15, 2003 21:27 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 1,920 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-03-000062 · edgar.xml · nonDerivative · entry 1 MUELLER PETER · CIK 0001256126 · CSO & SVP Drug Discovery 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,920 F1 · shares: Stock grant made under 1996 Stock and Option Plan, vesting in 4 equal annual installments from 12/11/2003. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.